New Alzheimer’s Drug Diranersen Targets Tau Protein to Slow Cognitive Decline
the staff of the Ridgewood blog
Ridgewood NJ, The landscape of neurodegenerative disease research is shifting. A novel Alzheimer’s treatment has successfully slowed clinical progression at a rate comparable to currently approved market drugs, according to data from a midstage clinical trial presented yesterday.
